Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 3/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731398 | 1.00 | ADRA1D (0.59) | ADRA1DADRA1AADRA1BHTR1ASMN1; SMN2 | |
| SCHEMBL4732783 | 1.00 | ADRA1D (0.59) | ADRA1DADRA1AADRA1BHTR1ASMN1; SMN2 | |
| SCHEMBL4728974 | 0.95 | ADRA1D (0.53) | ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4730883 | 0.92 | ADRA1D (0.52) | ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4729723 | 0.92 | ADRA1D (0.52) | ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4728449 | 0.91 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4874517 | 0.91 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4733169 | 0.91 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4867607 | 0.90 | ADRA1D (0.50) | ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL4727644 | 0.88 | ADRA1D (0.49) | ADRA1DADRA1AADRA1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221116-A1 | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-11 | — | — | US | claimed |
| WO-2008033513-A1 | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | WO | claimed |
| US-20080221116-A1 | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221116-A1 | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221116-A1 | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221116-A1 | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS | ADRA1D, ADRA1A, ADRB1 | ADRA1D 1/4885ADRA1A 2/4885ADRA1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.